GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harrow Inc (NAS:HROW) » Definitions » Net Income

Harrow (Harrow) Net Income : $-24.4 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Harrow Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Harrow's Net Income for the three months ended in Dec. 2023 was $-9.1 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-24.4 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Harrow's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.26.


Harrow Net Income Historical Data

The historical data trend for Harrow's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harrow Net Income Chart

Harrow Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 -3.36 -18.01 -14.09 -24.41

Harrow Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.06 -6.64 -4.23 -4.39 -9.15

Harrow Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Harrow's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-23.71+-0.701+0+0
=-24.4

Harrow's Net Income for the quarter that ended in Dec. 2023 is calculated as

Net Income(Q: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-9.683+0.535+0+0
=-9.1

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harrow  (NAS:HROW) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Harrow's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Harrow Net Income Related Terms

Thank you for viewing the detailed overview of Harrow's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Harrow (Harrow) Business Description

Traded in Other Exchanges
N/A
Address
102 Woodmont Boulevard, Suite 610, Nashville, TN, USA, 37205
Harrow Inc is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year.
Executives
Mark L Baum director, 10 percent owner, officer: Chief Executive Officer C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Martin A. Makary director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Van Horn R. Lawrence director 354 COOL SPRINGS BLVD., SUITE 106, FRANKLIN TN 37067
Andrew Boll officer: VP, Accounting and Reporting 437 S HWY 101, STE 209, SOLANA BEACH CA 92075
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Perry J. Sternberg director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Teresa Sparks director 40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Robert J Kammer director, 10 percent owner, officer: Chairman of the Board 1440 28TH STREET, SUITE 9, BOULDER CO 80303
Longboard Capital Advisors, Llc other: Institutional Investor 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad other: Managing Mbr of Longboard Cap. 1312 CEDAR ST., SANTA MONICA CA 90405
Clayton D Edwards officer: Chief Operating Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Anthony Principi director 2300 WEST PLANO PARKWAY, M/S D2420, PLANO TX 75244
Donald Paul Miloni 10 percent owner 1425 GREENWOOD LANE, GREENWOOD VILLAGE CO 80125
John P. Saharek officer: Chief Commercial Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130